Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM54FQA)

• Drug Name: Samuraciclib Drug Info
• Synonyms: Samuraciclib; ICEC0942; CT7001; ICEC-0942; ICEC0942 free base; 1805833-75-3; CT-7001; 46D4HS9ODA; 1805833-75-3 (free base); Samuraciclib HCl; (3~{R},4~{R})-4-[[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol; (3R,4R)-4-[[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol; 3-Piperidinol, 4-(((3-(1-methylethyl)-7-((phenylmethyl)amino)pyrazolo(1,5-a)pyrimidin-5-yl)amino)methyl)-, (3R,4R)-; ICEC 0942; (3r,4r)-4-[[[7-[(Phenylmethyl)amino]-3-Propan-2-Yl-Pyrazolo[1,5-A]pyrimidin-5-Yl]amino]methyl]piperidin-3-Ol; 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)-; Samuraciclib di-HCl; CT7001 di-HCl; SAMURACICLIB [INN]; UNII-46D4HS9ODA; CT-7001 di-HCl; CT7001 HCl; SAMURACICLIB [WHO-DD]; CT-7001 HCl; GTPL9903; CHEMBL4297488; SCHEMBL17032274; EX-A3445; BDBM50526797; NSC832261; NSC835588; NSC-832261; NSC-835588; HY-103712; (3R,4R)-4-((7-(benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5-ylamino)methyl)piperidin-3-ol dihydrochloride; (3R,4R)-4-({[7-(benzylamino)-3-(propan-2-yl)pyrazolo[1,5-a]pyrimidin-5-yl]amino}methyl)piperidin-3-ol; 3-Piperidinol,4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-,(3R,4R)-

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 1/2	[1]

• Cross-matching ID:
  PubChem CID: 91844733
  TTD Drug ID: DM54FQA

Molecule-Related Drug Atlas

Drug(s) Targeting Cyclin-dependent kinase 7 (CDK7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[5]
SY-1365	DMK48PM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
LY3405105	DMB51K2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
SY-5609	DMNW3LH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[9]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[9]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[9]
Pyrazolo-triazine derivative 2	DML6V78	N. A.	N. A.	Patented	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 7 (CDK7)	TTQYF7G	CDK7_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04802759) A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER). U.S.National Institutes of Health.
• [2] The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337.
• [3] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [4] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [5] Clinical pipeline report, company report or official report of BioTheryX.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
• [8] Clinical pipeline report, company report or official report of Syros Pharmaceuticals.
• [9] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.